This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
by Zacks Equity Research
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
NVSNegative Net Change BMRNPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
NVONegative Net Change LLYPositive Net Change ABBVNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
by Zacks Equity Research
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
RIGLPositive Net Change PCRXPositive Net Change ARGXNegative Net Change RCKTPositive Net Change
biotechs earnings
NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.
REGNNegative Net Change PCRXPositive Net Change NTLAPositive Net Change ARGXNegative Net Change
biotechs earnings
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
SNYNegative Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
SNYNegative Net Change BMRNPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
BMRNPositive Net Change GILDPositive Net Change FOLDPositive Net Change PCRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
by Zacks Equity Research
Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.
PCRXPositive Net Change ARGXNegative Net Change IOVANo Net Change ETNBPositive Net Change
biotechs cell-therapy earnings medical
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
by Zacks Equity Research
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
FOLDPositive Net Change PCRXPositive Net Change PBYIPositive Net Change IMCRPositive Net Change
biotechs
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BMRNPositive Net Change GILDPositive Net Change NBIXNegative Net Change XENENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
by Zacks Equity Research
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.
BMRNPositive Net Change GILDPositive Net Change FOLDPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
by Zacks Equity Research
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
SNYNegative Net Change NVONegative Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
BMRNPositive Net Change GILDPositive Net Change FOLDPositive Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
RIGLPositive Net Change PCRXPositive Net Change ARGXNegative Net Change MIRMPositive Net Change
biotechs earnings
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BMRNPositive Net Change GILDPositive Net Change FOLDPositive Net Change CPRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
by Zacks Equity Research
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
RHHBYNegative Net Change SRPTPositive Net Change ARWRNegative Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
BMRNPositive Net Change BEAMPositive Net Change FOLDPositive Net Change MDGLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.
BEAMPositive Net Change PCRXPositive Net Change ARGXNegative Net Change
biotechs earnings
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA
by Zacks Equity Research
BLUE and GILD are in the spotlight this week on key updates.
BMRNPositive Net Change GILDPositive Net Change TRDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
RDYPositive Net Change RIGLPositive Net Change BPMCPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
PCRXPositive Net Change ARGXNegative Net Change MIRMPositive Net Change SANAPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
PCRXPositive Net Change MIRMPositive Net Change CSTLPositive Net Change
biotechs
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
JNJPositive Net Change BMRNPositive Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Biotech Stocks This Earnings Season?
by Ahan Chakraborty
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
PRGONegative Net Change NVAXPositive Net Change NTLAPositive Net Change IOVANo Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals vaccines